Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

NTHIBullishIndustry Newsnews

High materiality8/10

NeOnc's NEO212 FDA meeting could define late-stage path

Sep 28, 2026, 9:55 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Regulatory interaction could clarify pathway and accelerate late-stage planning; paired with strong Phase 2a data and insider demand, this creates upside risk-reward ahead of potential pivotal trials.

AI summary

What happened, with direct paths to the underlying reporting

NeOnc schedules an FDA End-of-Phase 1 Type B meeting for NEO212 on November 17, 2026, to gauge population, design, and registrational potential. Positive guidance could shift NEO212 toward a defined late-stage plan while ongoing NEO100 Phase 2a data bolster the appetite for CNS cancer catalysts. With insider buying and new capital, near-term catalysts could drive re-rating if FDA feedback supports a clear pathway.

FDA End-of-Phase 1 Type B meeting for NEO212 set for Nov 17, 2026.
FDA feedback could define population, endpoints, and dose toward registrational path.
NEO100 Phase 2a: six-month PFS 48.9% and OS 26.09 months.
Insiders bought shares; Roth target cited; direct offering raised capital.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.